Pelthos Therapeutics Inc. PTHS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.6%+3.3pp | 76.3%+7.5pp | 68.7%— | —— | —— | |
| Operating margin | -157.7%+35.4pp | -193.1%+107pp | -300.4%— | —— | —— | |
| Net margin | -186.2%+71.7pp | -257.9%+60.5pp | -318.4%— | —— | —— | |
| EBITDA margin | -145.4%+36.4pp | -181.8%+109pp | -291.3%— | —— | —— | |
| Returns | ||||||
| Return on assets | -70.5%-4.8pp | -65.8%-29.1pp | -36.7%+491pp | -527.5%-230pp | -297.8%+788pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.1× | 0.3×+0.1× | 0.1×— | 0×— | 0×— | |
| Liquidity | ||||||
| Current ratio | 2.8×+0.7× | 2.1×0.0× | 2×+1.9× | 0.1×-0.1× | 0.2×-0.2× | |
| Quick ratio | 1.9×+0.7× | 1.1×+0.1× | 1×+0.9× | 0.1×-0.1× | 0.2×-0.2× | |
| Cash ratio | 1.3×+0.6× | 0.7×+0.1× | 0.6×+0.6× | 0×0.0× | 0×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.8×+0.8× | 0.1×0.0× | 0×— | —— | —— | |
| Debt-to-assets | 0.2×+0.2× | 0×0.0× | 0×— | —— | —— | |
| Interest coverage | -8.4×+2.4× | -10.8×+1.6× | -12.3×+5.6× | -17.9×— | —— | |
| Per Share | ||||||
| Book value per share | $10.60-48.7% | $20.68— | —— | —— | -$6.85-40.6% | |
| Valuation | ||||||
| Market capitalization | $98.22M+75.4% | $95.69M+11.4% | $85.9M— | —— | —— | |
| Enterprise value | $95.89M— | $81.1M+8.8% | $74.55M— | —— | —— | |
| Price / sales | 3.6×— | 5.7×-5.9× | 11.6×— | —— | —— | |
| Price / book | 2.6×— | 2.5×+1.0× | 1.5×— | —— | —— | |
| EV / sales | 3.1×— | 4.8×-5.2× | 10.1×— | —— | —— | |
| Earnings yield | -57.6%— | -45.3%-17.8pp | -27.5%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pelthos Therapeutics Inc.'s profit margins?
- Pelthos Therapeutics Inc. (PTHS) runs a 79.6% gross margin and a -157.7% operating margin, with a -186.2% net margin.
- Where do Pelthos Therapeutics Inc.'s ratios come from?
- Every ratio is computed from Pelthos Therapeutics Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
